Background: The FDA approved bimatoprost ophthalmic solution 0.03% for treatment of eyelash hypotrichosis in 2008. Consumer concern persists regarding potential side effects of this product.
Objective: To identify gaps in the safety information associated with the use of prostaglandin eyelash growth products.
Materials And Methods: Literature searches were performed using PubMed, Embase, and Nexis Uni databases without restriction to publication date, language, or study setting.
Results: The literature pertaining to bimatoprost for treatment of eyelash hypotrichosis is dominated by industry-sponsored clinical trials. Study design choices create gaps in our understanding of the clinical safety of these products.
Conclusion: Because of study design choice, clinical trials of bimatoprost for eyelash growth may have systematically underreported the incidence of drug application discomfort and prostaglandin-associated periorbitopathy. The risk of increased iris pigmentation remains inadequately investigated. Consequently, there is an ongoing need to educate and monitor patients who choose to use these products.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DSS.0000000000002928 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Will a glaucoma drug revolutionize the treatment of androgenetic alopecia? On drug repurposing, when the side effect becomes a desired therapeutic outcome].
Postepy Biochem
December 2024
Department of Biochemistry and Nutrition, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland.
Prostaglandins are hormones found in almost all mammalian tissues. As signaling molecules, they play a key role in the regulation of many physiological processes, including hair growth cycle. The article describes the history of the discovery of prostaglandins, including the work of Professor Ryszard Gryglewski – the discoverer of prostacyclin.
View Article and Find Full Text PDFChanges in prostaglandin-associated periorbital syndrome: a self-controlled and prospective study.
Cutan Ocul Toxicol
December 2024
Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China.
Article Synopsis
- The study investigated the incidence of the prostaglandin-associated periorbital syndrome (PAPS) in patients with primary open-angle glaucoma or ocular hypertension after using topical prostaglandin analogues (PGAs) for 3-6 months.
- Among the 55 patients studied, key indicators such as interpupillary distance and exophthalmos were measured, alongside subjective assessments of periocular changes, showing significant changes primarily at the 1 and 3-month marks.
- Results indicated that bimatoprost resulted in the highest incidence of PAPS, with noticeable periorbital changes like eyelash growth and hyperpigmentation increasing over time.
Green extraction of prostaglandin analogs in cosmetics using deep eutectic solvents and detection via LC-MS/MS.
J Chromatogr A
January 2025
Advanced Analysis Division, Toxicological Evaluation and Research Department, Ministry of Food and Drug Safety, Osong Health Technology Administration Complex, National Institute of Food and Drug Safety Evaluation, Cheongju-si, Chungcheongbuk-do 28159, Republic of Korea. Electronic address:
Prostaglandin analogs (bimatoprost, travoprost, tafluprost, etc.) have similar effects to prostaglandins and are effective drugs for treating glaucoma. These compounds exhibit abnormal reactions such as causing eyelash growth, with several cases being reported of people purchasing them to increase eyelash growth; however, some cases have reported side effects such as pigmentation and dry eyes.
View Article and Find Full Text PDFLow-dose oral minoxidil for frontal fibrosing alopecia: a 122-patient case series.
Actas Dermosifiliogr
November 2024
Departamento de Dermatología, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, España; Unidad de Tricología, Grupo de Dermatología Pedro Jaén, Madrid, España.
Article Synopsis
- * Out of 122 patients, 45.1% reported subjective improvements in hair density at the frontotemporal hairline, with varying degrees of improvement noted.
- * While 57.4% of patients saw overall hair density improvements, 33.6% experienced adverse effects, primarily hypertrichosis; however, the findings suggest that oral minoxidil can enhance hair and eyebrow growth in FFA patients.
Article Synopsis
- The ALLEGRO study assessed the effectiveness and safety of ritlecitinib, a treatment for alopecia areata (AA), focusing on patient-reported hair loss outcomes.
- Patients aged 12 and older with significant scalp hair loss participated in a 48-week trial comparing different dosages of ritlecitinib to a placebo.
- Results showed that 5-36% of ritlecitinib patients reported improved hair loss after 24 weeks, which correlated with positive changes in emotional symptoms and activity limitations, indicating the treatment's beneficial effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!